Pacific Biosciences of California, Inc.
PACB
$1.37
-$0.01-0.73%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 160.03M | 160.01M | 154.58M | 156.11M | 152.36M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 160.03M | 160.01M | 154.58M | 156.11M | 152.36M |
| Cost of Revenue | 111.10M | 117.55M | 108.61M | 113.09M | 114.67M |
| Gross Profit | 48.93M | 42.45M | 45.97M | 43.02M | 37.69M |
| SG&A Expenses | 134.18M | 143.19M | 163.48M | 176.13M | 185.83M |
| Depreciation & Amortization | 4.06M | 369.44M | 375.27M | 381.10M | 386.94M |
| Other Operating Expenses | 4.18M | 8.25M | 5.07M | 5.07M | 5.07M |
| Total Operating Expenses | 341.98M | 736.33M | 760.23M | 785.86M | 818.92M |
| Operating Income | -181.95M | -576.33M | -605.64M | -629.75M | -666.57M |
| Income Before Tax | -127.77M | -546.06M | -503.20M | -526.31M | -657.73M |
| Income Tax Expenses | 804.00K | 318.00K | 432.00K | 49.00K | 14.00K |
| Earnings from Continuing Operations | -128.58 | -546.38 | -503.63 | -526.36 | -657.75 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -128.58M | -546.38M | -503.63M | -526.36M | -657.75M |
| EBIT | -181.95M | -576.33M | -605.64M | -629.75M | -666.57M |
| EBITDA | -167.81M | -193.89M | -217.27M | -233.81M | -263.95M |
| EPS Basic | -0.43 | -1.84 | -1.69 | -1.79 | -2.29 |
| Normalized Basic EPS | -0.36 | -1.19 | -1.27 | -1.33 | -1.43 |
| EPS Diluted | -0.43 | -1.84 | -1.70 | -1.79 | -2.29 |
| Normalized Diluted EPS | -0.36 | -1.19 | -1.26 | -1.31 | -1.41 |
| Average Basic Shares Outstanding | 1.21B | 1.20B | 1.18B | 1.15B | 1.13B |
| Average Diluted Shares Outstanding | 1.21B | 1.20B | 1.20B | 1.18B | 1.15B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |